Published in Cancer Weekly, March 16th, 2004
The article is entitled "Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates."
Human and humanized antibodies typically have a serum half-life of approximately 3 weeks in humans. Maintaining serum half-life represents an important element of determining and providing appropriate drug exposure in the body.
PDL researchers, led by Naoya Tsurushita, PhD, engineered variants of human IgG...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.